Presenter: Philip Mease, University of Washington, Seattle, USA.
Saturday 15 June: 08:00–09:00 (Abstract LB0005)
The phase IV SPIRIT-H2H trial has enrolled 566 biologic-naïve participants with active psoriatic arthritis (PsA) and an inadequate response to one or more conventional DMARDs, and aims to assess the efficacy and safety of ixekizumab versus adalimumab. The primary outcome is the proportion of patients achieving both an ACR50 response and a PASI100 response at the 24-week follow-up.